biostudies-literatureLuciano MTNational Center for Advancing Translational SciencesNCATS NIH HHSMedical Research and Materiel CommandNational Institute on Alcohol Abuse and AlcoholismNIAAA NIH HHS157-166https://www.ebi.ac.uk/biostudies/studies/S-EPMC9974893biostudies-literatureUnknown36(1)Trauma-informed beliefs often decrease during posttraumatic stress disorder (PTSD) treatment. This may also extend to anxiety sensitivity (AS), defined as a fear of anxiety-related sensations and beliefs that anxiety is dangerous and/or intolerable. However, little is known about how AS changes during exposure-based and psychopharmacological PTSD treatments. Further, high AS may be a risk factor for diminished PTSD symptom improvement and increased treatment dropout. To better understand how AS impacts and is impacted by PTSD treatment, we conducted a secondary analysis of a randomized clinical trial with a sample of 223 veterans (87.0% male, 57.5% White) with PTSD from four U.S. sites. Veterans were randomized to receive prolonged exposure (PE) plus placebo (n = 74), sertraline plus enhanJournal of traumatic stressThe influence of posttraumatic stress disorder treatment on anxiety sensitivity: Impact of prolonged exposure, sertraline, and their combination.PMC9974893AA013525UL1 TR002240W81XWH‐11‐1‐0073T32 AA013525UL1TR000433UL1 TR000433Acierno RMartis BStein MBRauch SAMSzuhany KLTuerk PWAllard CBSimon NMPROGrESS Study TeamBaker AWLuciano MTNorman SBfalseThe influence of posttraumatic stress disorder treatment on anxiety sensitivity: Impact of prolonged exposure, sertraline, and their combination.Trauma-informed beliefs often decrease during posttraumatic stress disorder (PTSD) treatment. This may also extend to anxiety sensitivity (AS), defined as a fear of anxiety-related sensations and beliefs that anxiety is dangerous and/or intolerable. However, little is known about how AS changes during exposure-based and psychopharmacological PTSD treatments. Further, high AS may be a risk factor for diminished PTSD symptom improvement and increased treatment dropout. To better understand how AS impacts and is impacted by PTSD treatment, we conducted a secondary analysis of a randomized clinical trial with a sample of 223 veterans (87.0% male, 57.5% White) with PTSD from four U.S. sites. Veterans were randomized to receive prolonged exposure (PE) plus placebo (n = 74), sertraline plus enhan2023-01-01T00:00:00Z2023 Feb2025-04-26T11:48:38Z2025-02-19T04:59:45.419ZS-EPMC99748933645127110.1002/jts.22894